09.01.06
Fuji Health Science, Inc., Mount Laurel, NJ, has announced its parent company, Fuji Chemical Industry Co., Ltd., has been granted U.S. Patent No. 7,078,040, which involves inhibiting the expression of inflammatory cytokines and chemokines through the administration of astaxanthin. This new patent joins other Fuji patents for astaxanthin in areas such as muscle endurance, immunomodulation, gastric health and fertility. Fuji’s pending patents for astaxanthin include the areas of eye fatigue, wrinkle reduction, weight loss, diabetic nephropathy and dyspepsia.